Status:
COMPLETED
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
Lead Sponsor:
Allergan
Conditions:
Alopecia
Alopecia, Androgenetic
Eligibility:
All Genders
18-64 years
Phase:
PHASE1
Brief Summary
This study will investigate the safety, tolerability, and pharmacokinetics of new formulation of bimatoprost following topical application in patients with alopecia. Two formulations of bimatoprost wi...
Eligibility Criteria
Inclusion
- Males with moderate male-pattern baldness (androgenic alopecia)
- Females with moderate female pattern hair loss
- Non-smoker or smoker with at least 30 days abstinence from smoking/using nicotine-containing products
Exclusion
- Any dermatological condition of the scalp other than androgenic alopecia (males) or female pattern hair loss (females)
- Use of bimatoprost or other prostaglandin analogs within 3 months
- Prior use of scalp hair growth treatment (eg, finasteride, minoxidil) within 6 months
- Any prior hair growth procedures (eg, hair transplant or laser)
- Blood donation or equivalent blood loss within 90 days
- History of alcohol or drug addiction
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01189279
Start Date
October 1 2010
End Date
February 1 2011
Last Update
August 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tempe, Arizona, United States